Clinical trials: Mild to Moderate Asthma
Asthma
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
- Trial name
- NCT00044811
- Testing
- Fexofenadine
- Where
- 7 sites in United States, Costa Rica and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Asthma
A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)
The purpose of this study is to establish the safety and tolerability of Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) human rhinovirus 16 (RV16UB) in healthy and asthmatic participants, and…
- Trial name
- NCT01866306
- Testing
- RV16UB, LABA
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
- Trial name
- NCT07116889
- Testing
- GB-0895 (SC)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Generate Biomedicines
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective…
- Trial name
- NCT02322788
- Testing
- Terbutaline sulphate
- Where
- 4 sites in Canada, Netherlands and 1 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Asthma
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC.
- Trial name
- NCT00667992
- Testing
- Budesonide HFA, Budesonide CFC
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.
- Trial name
- NCT01641081
- Testing
- Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose
- Where
- 29 sites in United States
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
- Trial name
- NCT00449527
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 44 sites in United States
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Asthma
Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma.
The goal of this multi-centre, prospective, open-label, single-arm, post-market clinical follow-up study is to further strengthen the already existing clinical evidence for supportive treatment and symptoms alleviation in asthma…
- Trial name
- EIL-AST (NCT05699941)
- Testing
- Ectoin® Inhalation Solution
- Where
- 5 sites in Poland
- Volunteers
- 204 people
- Sponsor
- Bitop AG
Asthma
Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
The main objective of this study is to evaluate the efficacy, dose-ranging and initial safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 25 to 180 mcg per dosing in comparison to a DPI Placebo…
- Trial name
- NCT01581177
- Testing
- Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Albuterol MDI 90 mcg/inh
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
- Trial name
- NCT00546143
- Testing
- Omalizumab
- Where
- 5 sites in Germany, South Africa
- Volunteers
- 32 people
- Sponsor
- Novartis
Healthy Volunteer Study, Healthy Adults
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma.
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Trial name
- NCT07660731
- Testing
- PF-08103402, Midazolam
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough.
- Trial name
- NCT00624702
- Testing
- Indacaterol maleate
- Where
- 2 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Novartis
Asthma
A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers
This is a phase 1, first-in-human (FIH), multi-center, randomized, double-blind, placebo-controlled study of CSL311 in patients with mild-to-moderate asthma.
- Trial name
- NCT04082754
- Testing
- Human beta common receptor antagonist monoclonal antibody
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Asthma
Efficacy of TPI ASM8 During a 14-Day Allergen Challenge
This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days for the treatment of allergic asthma and…
- Trial name
- NCT01158898
- Testing
- TPI ASM8
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Syntara
Asthma
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial…
- Trial name
- NCT00235911
- Testing
- budesonide/formoterol Turbuhaler
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Asthma
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day
- Trial name
- NCT00272753
- Testing
- budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Asthma
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to…
- Trial name
- NCT01025648
- Testing
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel